This 78-year-old woman without prior history of diabetes developed CPI-DM approximately 17 days after receiving 1 dose of durvalumab (anti–PD-L1) and tremelimumab (anti–CTLA-4) for myelodysplastic syndrome. Here, CTLA4 is linked to diabetes mellitus.